Pharmaceutical Intermediates Market Size to Hit USD 57.65 Billion by 2034 - BioSpace

Jun 04, 2025

The pharmaceuticalintermediates market size was valued at USD 35.56 billion in 2024 andis projected to reach USD 57.65 billion by 2034, registering a CAGR of 4.95%from 2025 to 2034. The increasing prevalence of diseases, along with higherhealthcare expenditures, a growing demand for genericmedications, and an uptick in API production are all contributing to the risingdemand for pharmaceuticalintermediates.

Pharmaceutical Intermediates Market Key Takeaways

· North America held a market share of 34.0% in 2024.

· By product, the bulk drug intermediates segment is expected tocapture the biggest revenue share in 2024.

· By application, the analgesics segment is expected to acquire thelargest share in 2024.

· By end user, the CROs/CMOs segment registered the maximum marketshare in 2024.

TheComplete Study is Now Available for Immediate Access | Download the SamplePages of this Report@ https://www.novaoneadvisor.com/report/sample/5725

U.S. Pharmaceutical Intermediates Market Size and Growth2025 to 2034

The U.S. pharmaceutical intermediates market size reachedUSD 9.3 billion in 2024 and is anticipated to be worth around USD 15.1 billionby 2034, poised to grow at a CAGR of 4.5% from 2025 to 2034.

North America Dominates the Pharmaceutical IntermediatesMarket. North America has been the key player in the pharmaceuticalintermediates market due to the presence of some of the top drug companies andthe advanced health care infrastructure and strong research and developmentcapabilities. With the rise of new products and the increased approval of newdrugs, the need for intermediates has risen consequently and contractmanufacturing has become an important business model for the outsourcing ofproduction.

U.S. Leads Pharmaceutical Intermediates Market withR&D Investment and Outsourcing Growth

United States Leads the pharmaceutical intermediates marketin North America, driven by the ongoing R&D efforts and increased demandfor complex intermediates in both traditional and biologic drug formulations.CMOs take up a lot of the contract manufacturing business, both to bring thecost of production down and to increase production, which, in turn, isessential for new and specialized intermediates.

· On January 16, 2024, Willow Biosciences partnered withEnterin Inc. to develop sustainable manufacturing processes for keyintermediates and active pharmaceutical ingredients (APIs) forneurodegenerative treatments.

APAC Emerges as a Powerhouse in PharmaceuticalManufacturing Driven by Skilled Workforce

The Asia Pacific region is emerging out as a powerhouseregion in the pharmaceutical intermediates market which is being acceleratedwith the recent industrial revolution and also huge investments that are beingmade in each of the countries, China, South Korea, Australia etc. These factorsare one of the primary reasons that are increasing the region’s pharmaceuticaloutput and also its capability to attract major investments in the area ofoutsourced manufacturing.

· In 2024, Jiangsu Run'an Pharmaceutical Co. Ltd. participated inCPHI China to expand its international customer base and enhance global marketpresence.

The pharmaceutical industry has initiated a regime in whichIndia is now ranked as the prime country in the APAC region for itsmanufacturing for the very first time. The only way the country has been ableto create a market for itself is by hiring low-skilled workers and employingmany scientists and engineers.

The Pharmaceutical Intermediates Market involves as a sectorin the production and sale of chemical compounds utilized as precursors in theactive pharmaceutical ingredient (APIs) manufacturing process. These intermediatesare an important part of the drug formulation and production process. Themarket is driven by increasing demand for generic drugs, advancements in drugdevelopment, and the growing healthcare needs worldwide which lead toinnovations in chemical processes and production efficiency.

The increasing emphasis on biopharmaceuticals, includingmonoclonal antibodies, recombinant proteins, and gene therapies, presentssubstantial opportunities for suppliers in the pharmaceutical intermediatesmarket. The rising demand for intermediates such as cell culture media, growthfactors, and purification reagents—fueled by progress in biotechnologyand personalizedmedicine, creates pathways for market growth.

Moreover, the growing international demand for medicines,which is driven by an increase in the average age of people and the rise innon-communicable diseases, represents a further expansion path.

AI has a significant role in the pharmaceutical ingredientmarket. It is making possible the development of drug products that have notexisted before by prognosticating probable formulations and releasingmechanisms. AI is further utilized to optimize the efficiency of existingsynthesis pathways, hereby leading to less waste and lower environmentalimpacts. Additionally, it helps to find new uses for old intermediates whichwiden their market application beyond the traditional ones.

Market Trends

· Growing Investment in R&D: Higher R&D spendingthat is targeted at new drugs is the reason for the need of traditional andcomplex intermediates in drug manufacturing that are used as a part of theproduction process. More efficient and time-consuming processes are beingfollowed due to these new requirements that.

· Emphasis on Outsourcing: Companies attain cost savings andincrease operating efficiency through strategic business relationships withContract Manufacturing Organizations (CMOs). The knowledge of CMOs in the fieldof intermediate production allows pharmaceutical companies to free theirdepartments to R&D and marketing exclusively.

· Dominance of Bulk Drug Intermediates: Bulk drugintermediates play a significant role in large-scale production of ActivePharmaceutical Ingredient (API), and they are particularly crucial inthe case of generic drugs. Therapeutic areas of cancer and heart diseases havethe largest number of patients who take generic drugs.

· Focus on Sustainable Production: Green chemistry andbiocatalysis are the two up-and-coming (innovative) methods/types ofpharmaceutical intermediate production. Acting as the "green"alternative, these ways result in less pollution and allow for more orderlyproduction.

Report Scope of PharmaceuticalIntermediates Market

Report Coverage

Details

Market Size in 2025

USD 37.32 Billion

Market Size by 2034

USD 57.65 Billion

Growth Rate From 2025 to 2034

CAGR of 4.95%

Base Year

2024

Forecast Period

2025-2034

Segments Covered

Product, Application, and End User

Market Analysis (Terms Used)

Value (US$ Million/Billion) or (Volume/Units)

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Key Companies Profiled

The major players operating in the pharmaceutical intermediates market are BASF SE, Aceto Corporation, Sanofi SAIS, Chiracon GmbH, Yin-sheng Bio-tech Co. Ltd., Dishman Group, Green Vision Life Sciences, Midas Pharma GmbH, Vertellus Holdings LLC., Lonza Group.

Segment Insights

Product Insights

The bulk drug intermediates that generated the maximumamount of revenue in 2024, were responsible for their widespread use in theproduction of ActivePharmaceutical Ingredients (APIs). These products are known for thetherapeutic effects they provide as drug components. Government initiativesaimed at promoting bulk drug parks are expected to boost the growth of thissector through supportive policies and increased local manufacturing.

Customized intermediates are expected to be the segment withthe highest growth as they consist of the adjustment of the molecules to reachcertain curative effects. This section is becoming more attractive to theindustry because thanks to it one can create the doses that would be best forthe patient with the least side effects.

By Application Insights

Based on application, the analgesics segment accounted foraround 31.0% of the global pharmaceutical intermediates market and is likely toremain its leadership due to the escalating occurrence of chronic diseases(arthritis, cancer, and cardiovascular conditions, etc.) leading to an increasein the demand for pain relief medications.

Conversely, the anti-cancer drugs segment is forecast toregister a strong growth rate predominantly due to the upswing of cancerincidences that are taking place across the world. The segment will outstripthe others in the market with over 35 million new cases in 2050 according tothe WHO.

By End User Insights

The CROs/CMOs segment is projected to dominate the globalpharmaceutical intermediates market in 2024, driven by the swift growth andincreasing impact of contract research and manufacturing organizations. Thistrend has greatly increased the demand for intermediates utilized in drugproduction and research, solidifying the segment's ongoing dominance.

Research laboratories are anticipated to be thefastest-growing segment, thanks to rising private investments in pharmaceuticalresearch. This influx of funding for new drug development is expected to drivesignificant growth in the segment throughout the forecast period.

Immediate Delivery is Available | Get Full Report Access@ https://www.novaoneadvisor.com/report/checkout/5725

Related Report

· Pharmaceutical Analytical Testing Market - https://www.precedenceresearch.com/pharmaceutical-analytical-testing-market

· Pharmaceutical Intermediates Market - https://www.precedenceresearch.com/pharmaceutical-intermediates-market

· Active Pharmaceutical Ingredients Market - https://www.precedenceresearch.com/active-pharmaceutical-ingredient-market

Pharmaceutical Intermediates Market Top Companies

· Aceto Corporation

· BASF SE

· Chiracon GmbH

· Dishman Group

· Green Vision Life Sciences

· Lonza Group

· Midas Pharma GmbH

· Sanofi SAIS

· Vertellus Holdings LLC.

· Yin-sheng Bio-techCo. Ltd.

Pharmaceutical Intermediates Market Recent Development

· In October 2024, Lonza extended its long-term collaboration withleading global biopharmaceutical companies for the manufacturing ofantibody-drug conjugates, strengthening its position in the biopharmaceuticalsector.

· On June 25, 2024, DSM-Firmenich launched CBtru®, an advancedcannabidiol (CBD) drug product intermediate designed for oral solid deliveryformats, aiming to elevate patient health with innovative formulations.

· On March 22, 2024, YongNong announced the commencement ofproduction for intermediates as part of its 50,000-ton L-glufosinate capacity,enhancing its agricultural product portfolio.

Segments Covered in the Report

This report forecasts revenue growth at country levels andprovides an analysis of the latest industry trends in each of the sub-segmentsfrom 2021 to 2034. For this study, Nova one advisor, Inc. has segmented thePharmaceutical Intermediates Market

By Product

· Chemical Intermediates

· Bulk Drug Intermediates

· Custom Intermediates

By Application

· Analgesics

· Ant-inflammatory Drug

· Cardiovascular Drugs

· Anti-Diabetic Drugs

· Anti-Cancer Drugs

· Others

By End User

· Biotech and Pharma Companies

· Research Laboratory

· CMO/CRO

By Regional

· North America

· Europe

· Asia Pacific

· Latin America

· Middle East and Africa (MEA)

Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/5725

USA: +1 804 441 9344

APAC: +61 485 981 310 or +91 87933 22019

Europe: +44 7383 092 044

Email: [email protected]

Web: https://www.novaoneadvisor.com/

You can place an order or ask any questions, please feelfree to contact at [email protected]| +1 804 441 9344